Stockscreener 앱 받기
1.40
1.45%
0.02
시간 외 거래:
1.40
전일 마감가:
$1.38
열려 있는:
$1.38
하루 거래량:
1.47M
Relative Volume:
0.49
시가총액:
$226.77M
수익:
-
순이익/손실:
$-274.18M
주가수익비율:
-0.5524
EPS:
-2.5346
순현금흐름:
$-198.33M
1주 성능:
-7.89%
1개월 성능:
-17.16%
6개월 성능:
-88.36%
1년 성능:
-90.55%
1일 변동 폭
$1.36
$1.435
1주일 범위
$1.26
$1.49
52주 변동 폭
$1.26
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
명칭
Neumora Therapeutics Inc
전화
(857) 760-0900
주소
490 ARSENAL WAY, SUITE 200, WATERTOWN
NMRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.40 | 226.77M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-03-07 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-07-08 | 개시 | Mizuho | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Hold |
| 2023-10-10 | 개시 | BofA Securities | Buy |
| 2023-10-10 | 개시 | Guggenheim | Buy |
| 2023-10-10 | 개시 | JP Morgan | Overweight |
| 2023-10-10 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-10 | 개시 | Stifel | Buy |
| 2023-10-10 | 개시 | William Blair | Outperform |
모두보기
Neumora Therapeutics Inc 주식(NMRA)의 최신 뉴스
ROSEN, THE FIRST FILING FIRM, Encourages Neumora - GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, THE FIRST FILING FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA - GlobeNewswire Inc.
Lead Plaintiff Deadline Approaching in NMRA: Kessler Topaz - GlobeNewswire
Lead Plaintiff Deadline Approaching in NMRA: Kessler Topaz Meltzer & Check, LLP Reminds Investors a Securities Fraud Class Action Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - TradingView
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Neumora Therapeutics, Inc.(NMRA) Shareholders - ACCESS Newswire
Class Action Filed Against Neumora Therapeutics, Inc. - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - PR Newswire
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) See - GuruFocus.com
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. - GlobeNewswire
NMRA CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investorsa Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) | FinancialContent - Financial Content
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-03-12 | Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
2025-03-11 | Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class ActionNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Neumora Therapeutics, Inc of Class Action Lawsuit and Upcoming DeadlinesNMRA - PR Newswire
NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation - PR Newswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Equities Analysts Issue Forecasts for NMRA Q1 Earnings - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Downgraded to Market Perform Rating by William Blair - Defense World
Neumora cut to Hold at Stifel after J&J’s VENTURA exit - MSN
NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
2025-03-10 | Shareholders that Lost Money on Neumora Therapeutics, Inc. (NMRA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:NMRA | Press Release - Stockhouse Publishing
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNMRA - ACCESS Newswire
2025-03-10 | NMRA LAWSUIT ALERT: Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:NMRA | Press Release - Stockhouse Publishing
Neumora Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationNMRA - ACCESS Newswire
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - StreetInsider.com
Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA - ACCESS Newswire
Neumora stock rating cut to Market Perform at William Blair - Investing.com
Neumora stock holds Buy rating and $18 target from H.C. Wainwright - Investing.com
William Blair Downgrades Neumora Therapeutics (NASDAQ:NMRA) to Market Perform - MarketBeat
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by William Blair to Market Perform - MarketBeat
William Blair Downgrades Neumora Therapeutics to Market Perform From Outperform -March 10, 2025 at 07:50 am EDT - Marketscreener.com
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: - GlobeNewswire
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds ... - The Bakersfield Californian
Neumora Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 7, 2025 to Discuss Your RightsNMRA - Morningstar
HC Wainwright Issues Optimistic Estimate for NMRA Earnings - MarketBeat
Head-To-Head Analysis: Cidara Therapeutics (NASDAQ:CDTX) vs. Neumora Therapeutics (NASDAQ:NMRA) - Defense World
What is William Blair's Forecast for NMRA Q1 Earnings? - MarketBeat
2025-03-09 | Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your RightsNMRA | NDAQ:NMRA | Press Release - Stockhouse Publishing
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora - GlobeNewswire
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc.(NMRA) - ACCESS Newswire
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
2025-03-09 | NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:NMRA | Press Release - Stockhouse Publishing
Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to “Hold” at Stifel Nicolaus - Defense World
Neumora Therapeutics Inc (NMRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):